Novo Nordisk's U.S.-traded shares dropped over 5% after the company raised its 2026 sales and profit outlook but projected adjusted sales and operating profit to decline up to 6% or remain flat at constant exchange rates. The company reported a 3% rise in second-quarter sales and an 11% increase in adjusted operating profit, boosted by the launch of a pill and higher-dose injection version of its Wegovy weight loss drug. Despite these product successes, the cautious guidance disappointed investors ahead of earnings reports from Novo Nordisk and rival Eli Lilly. The results highlight ongoing competition in the GLP-1 drug market, where Eli Lilly currently leads in market share.
Novo Nordisk raised its full-year sales and profit outlook, expecting a smaller decline than previously forecasted, driven by strong GLP-1 product sales including the Wegovy pill. However, analysts remain cautious as the better-than-expected quarter ...
Citi maintained a neutral rating on Novo Nordisk following the failure of its heart drug ziltevekimab in the ZEUS trial, which showed no benefit over placebo in reducing cardiovascular events. Despite this setback, the drug's expected peak sales are ...
Citi maintains a neutral rating on Novo Nordisk after its anti-inflammatory drug ziltevekimab failed to meet the primary endpoint in a heart disease trial. The trial showed no significant benefit over placebo and raised safety concerns. While Citi vi...
SpaceX will release its first public earnings report focusing on Starlink's growth, Starship development, and capital spending. Despite shares falling over 50% from their peak and trading below the IPO price, Wall Street remains optimistic with bulli...
As employers increasingly drop insurance coverage for GLP-1 weight-loss drugs like Wegovy and Zepbound, major retailers such as Walmart, Costco, CVS, and Amazon are expanding direct-to-consumer prescription programs to capture market share. These pro...
